Effect of epigallocatechin-3-gallate on graft-versus-host disease

5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment might not be an effective therapy against GvHD in the clinic.

Cite

CITATION STYLE

APA

Choi, J., Cooper, M. L., Ziga, E. D., Ritchey, J., & DiPersio, J. F. (2014). Effect of epigallocatechin-3-gallate on graft-versus-host disease. Cell Transplantation, 23(9), 1163–1166. https://doi.org/10.3727/096368913X667691

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free